Neovascular age-related macular degeneration (nAMD) is among the leading causes of blindness worldwide. Although the availability of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have shifted the care paradigm for nAMD, the need for frequent injections is a major contributor to the burden of this disease. Consequently, newer treatment strategies that simplify patient care, improve patient satisfaction, increase treatment compliance, and lower the burden of nAMD have been highly sought after.
In this CME activity, 2 leading retina specialists analyze key data on approved and emerging anti-VEGF therapies for nAMD, focusing on the implications of newer agents and dosing regimens on easing the burden of treatment associated with this disease.
Upon completion of this activity, participants should be better able to:
Clinical Professor, Ophthalmology
Cullen Eye Institute, Baylor College of Medicine
Vice Chair, Research
Blanton Eye Institute, Houston Methodist Hospital
Director, Research
Retina Consultants of Texas
San Antonio, TX
Retina Specialist, Ophthalmology Clinic
Tennessee Retina
Nashville, TN
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
